In mild to moderate AD
Reach for EUCRISA for patients under your care

EUCRISA is the first and only topical PDE-4 inhibitor indicated for the topical treatment of mild to moderate AD in patients 2 years of age and older.¹ ²

AD=atopic dermatitis; PDE-4=phosphodiesterase-4.
* Comparative clinical significance unknown.
Significantly more patients achieved success in ISGA at Day 29 vs. vehicle (31.4% vs. 18%; \( p \leq 0.001 \))

**Success in ISGA:**
defined as score of CLEAR (0) or ALMOST CLEAR (1) and \( \geq 2 \)-grade improvement from baseline at Day 29

† Actual case. Individual results may vary. May not represent results for all patients. Adapted from Paller A, et al.

‡ Results from the AD-302 study: a multicentre, double-blind, parallel-group, vehicle-controlled trial of patients aged 2–79 years (mean: 12.6 EUCRISA group; 11.8 vehicle group) with a 5–95% treatable body surface area (baseline mean: 17.9% EUCRISA group; 17.7% vehicle group). Patients were randomized 2:1 to receive EUCRISA (n=513) or vehicle (n=250) applied twice daily for 28 days.

ISGA=Investigator's Static Global Assessment.
Proven safety and tolerability profile

4-WEEK PIVOTAL TRIALS

<table>
<thead>
<tr>
<th>Adverse reactions occurring in ≥1% of patients in the 4-week pivotal trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPLICATION SITE PAIN §</td>
</tr>
<tr>
<td>4.45% (n=45)</td>
</tr>
<tr>
<td>EUCRISA (N=1012)</td>
</tr>
</tbody>
</table>

48-WEEK, OPEN-LABEL, SINGLE-ARM, LONG-TERM SAFETY STUDY ¶

Most frequently reported adverse events in patients receiving EUCRISA intermittently (n=517) included:
- Atopic dermatitis
- Application site pain §
- Application site infection

Discontinuation rate due to adverse events was 2%.

§ Application site pain refers to skin sensations such as burning or stinging.
¶ 517 patients (including 454 patients aged 2–17 years) who completed the 28-day pivotal trials without safety issues that precluded further treatment were treated with EUCRISA intermittently for up to 48 weeks in 28-day on-treatment or off-treatment cycles.
Consider EUCRISA as part of your treatment plan for patients with mild to moderate AD

Apply thin layer topically twice daily
Ages 2 and up
Anywhere on affected skin

Relevant warnings and precautions
• Hypersensitivity reactions, including contact urticaria
• Use in pregnant and nursing women
• Use in geriatric patients

For more information
Consult the Product Monograph at http://pfizer.ca/pm/en/Eucrisa.pdf for information regarding adverse reactions, drug interactions, and dosing. The Product Monograph is also available by calling 1-800-463-6001.


Clinical significance unknown.